Cervical cancer articles from across Nature Portfolio

The COMPASSION16 trial showed survival benefits of cadonilimab plus standard therapy in advanced cervical cancer. Here, subgroup analysis confirms consistent progression-free and overall survival improvements across diverse patient profiles.

Cervical cancer is a largely preventable disease that yet has a high burden and mortality rate in Africa. In here the authors review, the advancement in cervical cancer screening, treatment, and prognosis and advocate for decisive measures to enhance screening methods

Van Keer et al. explore an entirely molecular cervical screening approach based on HPV and DNA methylation analysis in at-home collected urine from 454 women. The ASCL1/LHX8 methylation test detects nearly all cancers and a majority of CIN3, supporting the potential of full molecular screening in urine by primary HPV testing and methylation triage.

The antibody–drug conjugate (ADC) tisotumab vedotin resulted in improved progression-free and overall survival, leading to FDA approval and a new treatment option for patients.